EUROPRISE
EUROPRISE 2007-2012 is a European ‘super-network’ of scientists leads fight against HIV/AIDS infection
The European AIDS Treatment Group is one of the partners involved in EUROPRISE, a five-year project that stands for successful development of preventative strategies against HIV-1: microbicides, vaccines or their combined effects (See the consortium partners).
EUROPRISE brought together EU scientists from both microbicide and vaccine fields to embrace a coordinated approach to HIV-1 prevention research. AIDS researchers from 10 countries are pooling their knowledge in a bid to develop vaccines and microbicides which could work together to stop the virus being transmitted. The EUROPRISE network comprises leading scientists from 32 institutions – from universities to pharmaceutical companies such as GlaxoSmithKline and Novartis – in an ambitious European project on biomedical HIV prevention.
In this respect, EUROPRISE is the first network, both in Europe and internationally to deliberately bring these scientists together in a truly integrated fashion.
The successful development of preventative strategies against HIV-1 (microbicides, vaccines or their combined effects) would provide a pivotal turning point in global efforts to combat the pandemic spread of AIDS providing an incalculable impact on solving societal problems associated with this disease.
EUROPRISE hopes to produce a vaccine and a vaginal microbicide (topically applied drugs to prevent infection), which women can use alone or in combination to stop transmission of the virus during sex.
EUROPRISE started on January 1st 2007 and received a €15.5 million grant from the European Commission.
For additional information on Europrise, visit the network’s web site, www.europrise.org
EATG project leader : David Haerry
EATG project coordinator : Laure Sonnier
The EUROPRISE taskforce has 13 members.
More...
